Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Verrica Pharmaceuticals (VRCA) Change in Acquisitions & Divestments (2021 - 2022)

Verrica Pharmaceuticals has reported Change in Acquisitions & Divestments over the past 2 years, most recently at $7.0 million for Q4 2022.

Quarterly results put Change in Acquisitions & Divestments at $7.0 million for Q4 2022, down 50.7% from a year ago — trailing twelve months through Sep 2023 was $7.0 million (down 89.43% YoY), and the annual figure for FY2022 was $59.0 million, down 14.48%.
Change in Acquisitions & Divestments for Q4 2022 was $7.0 million at Verrica Pharmaceuticals, up from $2.0 million in the prior quarter.
Over the last five years, Change in Acquisitions & Divestments for VRCA hit a ceiling of $47.5 million in Q1 2022 and a floor of $2.0 million in Q3 2022.